Zofecard Plus 30 mg/12,5 mg filmom obložene tablete
| Name | Zofecard Plus 30 mg/12,5 mg filmom obložene tablete |
|---|---|
| Marketing Authorisation Number | HR-H-491184727 |
| Active Substance | zofenoprilkalcij hidroklorotiazid |
| Composition | jedna filmom obložena tableta sadrži 30 mg zofenoprilkalcija i 12, 5 mg hidroklorotiazida |
| Pharmaceutical Form | filmom obložena tableta |
| Manufacturer | Menarini-Von Heyden GmbH, Dresden, Njemačka;
A. Menarini Manufacturing Logistics And Services S.r.l., L'Aquila, Italija |
| Marketing Authorisation Holder | Berlin-Chemie Menarini Hrvatska d.o.o., Horvatova 80a, Zagreb |
| Marketing Authorisation Date | 09.05.2018 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/16-02/561 |
| Registration Number | 381-12-01/38-18-05 |
| Prescription | na recept |
| Type of prescription | ponovljivi recept |
| Distribution | u ljekarni |
| Advertising to general public | zabranjeno |
| ATC Code | C09BA15 |
| Medicinal product marketed in the Croatia | Da |
| SmPC | download |
| PL | download |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
